B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

STK26

MOLECULAR TARGET

serine/threonine kinase 26

UniProt: Q9P289NCBI Gene: 5176530 compounds

STK26 (serine/threonine kinase 26) is targeted by 30 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting STK26

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1tozasertib4.3375
2ruxolitinib4.2368
3bosutinib4.0858
4dinaciclib3.8747
5silmitasertib3.7843
6neratinib3.6638
7nintedanib3.6136
8tae 6843.4330
9fedratinib3.4029
10gilteritinib3.4029
11linifanib3.3327
12dovitinib3.0921
13jnj 77066213.0921
14lestaurtinib3.0420
15pf 037583093.0019
16danusertib2.9418
17cediranib2.8316
18pf 005622712.7715
19hesperadin2.7715
20pha 6657522.7114
21crenolanib2.7114
22kw 24492.6413
23gsk 6906932.6413
24su 0148132.208
25decernotinib2.208
26cyc 1162.087
27enzastaurin2.087
28amg 9002.087
29Crizotinib0.691
30Dasatinib0.691

About STK26 as a Drug Target

STK26 (serine/threonine kinase 26) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 30 compounds with documented STK26 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

STK26 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.